Draft:DrugsData
| Submission declined on 23 November 2024 by Frostly (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Type of site | Drug testing and analysis database |
|---|---|
| Available in | English |
| URL | DrugsData.com |
| Commercial | No |
| Registration | Optional |
| Launched | 2001 |
| Current status | Active |
DrugsData, formerly known as EcstasyData, is an online database that collects and publishes laboratory testing results for psychoactive substances. Established in 2001, the service is designed to promote public health and harm reduction by providing accurate information about the contents of street drugs. It is a key resource for individuals, health professionals, and researchers who aim to better understand the composition of drugs sold illicitly.[1]
Overview
[edit]DrugsData allows users to anonymously submit drug samples to be tested by professional laboratories. The results are then published on the website, detailing the chemical composition, weight, and appearance of the substance. The service focuses on substances sold as MDMA (commonly known as ecstasy) but includes a wide range of psychoactive drugs such as stimulants, hallucinogens, and synthetic cannabinoids.[2]
The website serves as an educational tool, helping users identify potentially dangerous adulterants, mislabeled substances, or unanticipated active ingredients. By providing this information, DrugsData seeks to reduce risks associated with drug use and support harm reduction practices.[3]
History
[edit]DrugsData was initially launched as EcstasyData in 2001 by the nonprofit organization Erowid. The service was created in response to the increasing prevalence of adulterated MDMA tablets and powders in the illicit drug market. Over time, the scope of the project expanded to include a broader range of substances, prompting a rebranding to DrugsData.[4]
Functionality
[edit]Users can submit drug samples anonymously to laboratories partnered with DrugsData. Each submission is tested using advanced methods such as gas chromatography–mass spectrometry (GC-MS) or high-performance liquid chromatography (HPLC). Results are published on the website with visual identifiers, including photographs of the substance and detailed reports. [2]
Key features of the website include:
- A searchable database of tested substances
- Photographs and descriptions of each tested sample
- Detailed chemical composition, including any adulterants
- Alerts about particularly dangerous or unusual findings
Impact
[edit]DrugsData is widely regarded as a valuable resource for public health and harm reduction. The service has been cited in academic research, media reports, and educational campaigns addressing drug safety. It provides critical information to recreational drug users, health professionals, and policymakers about trends in drug adulteration and purity.[5] [6]
Limitations
[edit]Although DrugsData provides reliable chemical analyses, it is not intended to encourage drug use. Testing is limited by the availability of laboratories and the scope of substances analyzed. Additionally, users are responsible for covering the cost of testing, which may restrict accessibility for some individuals.[6]
References
[edit]- ^ "DrugsData Official Website". Retrieved 2024-11-22.
- ^ a b Gable, Robert (2004). "Ecstasy (MDMA) and its Analogs: A Review of the Literature". Journal of Psychoactive Drugs. 36 (3): 239–248. doi:10.1080/02791072.2004.10399891.
- ^ "Harm Reduction: How it Reduces the Negative Effects of Substance Use". Rehabs.org. Retrieved 2024-11-22.
- ^ "Erowid Official Website". Retrieved 2024-11-22.
- ^ "Harm Reduction and Risk Management | Drug Policy Facts". www.drugpolicyfacts.org. Retrieved 2024-11-22.
- ^ a b Michael C. (2023-07-14). "Revolutionizing Street Drug Testing: The Role of DrugsData". The New York Times. Retrieved 2024-11-22.